Previous issue | Volume 86 | ESPE2016 | Next issue

55th Annual ESPE

Paris, France
10 Sep 2016 - 12 Sep 2016

Card image cap
Paris, France: 10-12 September 2016 Further information

Rapid Free Communications

Growth: Clinical

Somavaratan (VRS-317) Treatment of Children with Growth Hormone Deficiency (GHD): Results at 2 Years (NCT02068521)
aVersartis, Inc., Menlo Park, CA, USA; bChildren’s Mercy Hospital and University of Missouri-Kansas City, Kansas City, MO, USA; cSierra Medical Research, Clovis, CA, USA; dMary Bridge Children’s Hospital, Tacoma, WA, USA; eUniversity of Minnesota Masonic Children’s Hospital, Minneapolis, MN, USA; fSeattle Children’s Hospital, Seattle, WA, USA; gResearchPoint Global, Austin, TX, USA
hrp0086rfc8.1
Pharmacokinetic Modelling Predicts Native hGH Levels Following Administration of a Sustained-Release Prodrug, TransCon hGH, to Children with GHD
aAscendis Pharma Inc., Palo Alto, USA; bAscendis Pharma A/S, Hellerup, Denmark; cAscendis Pharma GmbH, Heidelberg, Germany
hrp0086rfc8.2
A Hybrid Fc-fused Human Growth Hormone, GX-H9, Shows a Potential for Weekly and Semi-monthly Administration in Clinical Studies
aYonsei University, Seoul, Republic of Korea; bUniversity of Munich Medizinsche Klinik, Munich, Germany; cInstitue of Endocrinology and Metabolism named after Komisarenko NAMS of Ukraine, Kyev, Ukraine; dGenexine, Inc., Seongnam, Republic of Korea; eHandok, Inc., Seoul, Republic of Korea
hrp0086rfc8.4
A Six-Month Safety and Efficacy Study of TransCon hGH Compared to Daily hGH in Pre-Pubertal Children with Growth Hormone Deficiency (GHD)
aDiv. Endocrinologie Pediatrique - Hopital Mere-Enfant, University Claude Bernard Lyon1, Lyon, France; bBashkir State Medical University, Ufa, Russia; c2nd Children City Clinic, Minsk, Belarus; dKharkiv National Medical University, Kharkiv, Ukraine; eAscendis Pharma A/S, on behalf of the TransCon hGH Study Group, Hellerup, Denmark
hrp0086rfc8.6
Safety and Tolerability of Once-Weekly Administration of CTP-Modified Human Growth Hormone (MOD-4023): 24-month Complete Dataset Results of a Phase 2 Study in Children with Growth Hormone Deficiency
aUkrainian Children Specialized Clinical Hospital, Kyev, Ukraine; bSt. Petersburg State Pediatric Medical Academy, St. Petersburg, Russia; cBashkir State Medical University, Ufa, Russia; dOregon Health & Science University, Oregon, USA; eKaplan Medical Center, Rehovot, Israel; fOPKO Biologics, Nes Ziona, Israel; g2nd Children City Clinic, Minsk, Belarus
hrp0086rfc8.7
Efficacy of Once-Weekly Administration of CTP-Modified Human Growth Hormone (MOD-4023): 24-month Complete Database Results of a Phase 2 Study in Children with Growth Hormone Deficiency
aUkrainian Children Specialized Clinical Hospital, Kyev, Ukraine; bSt. Petersburg State Pediatric Medical Academy, St. Petersburg, Russia; cBashkir State Medical University, Ufa, Russia; dOregon Health & Science University, Oregon, USA; eKaplan Medical Center, Rehovot, Israel; fOPKO Biologics, Nes Ziona, Israel; g2nd Children City Clinic, Minsk, Belarus
hrp0086rfc8.8